Immunogenicity of Two Doses of BNT162b2 mRNA COVID-19 Vaccine with a ChAdOx1-S Booster Dose among Navy Personnel in Mexico

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Follow‐Up and Comparative Assessment of SARS‐CoV‐2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA‐1273 Heterologous Booster Vaccination2024 · 2 citations
2. 2Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines2022 · 270 citations
3. 3Humoral and Cellular Responses to BNT162b2 as a Booster Following Two Doses of ChAdOx1 nCov-19 Determined Using Three SARS-CoV-2 Antibody Assays and an Interferon-Gamma Release Assay: A Prospective Longitudinal Study in Healthcare Workers2022 · 12 citations
4. 4Immunogenicity and Durability of Antibody Responses to homologous and heterologous Vaccination with BNT162b2 and ChAdOx1 Vaccines for COVID-19 46652025
5. 5Longevity and Magnitude of Antibody Responses After Homologous and Heterologous COVID-19 Booster Vaccinations in Bangladesh2026